Botulinum toxin B in the treatment of craniofacial hyperhidrosis.

Abstract

BACKGROUND:

Hyperhidrosis affects up to 3% of the population and negatively affects patients' quality of life. Craniofacial hyperhidrosis is a common complaint which has been successfully treated with botulinum toxin B (Btx B) since 2004 at our hidrosis clinics.

OBJECTIVE:

To evaluate the safety and clinical effect of Btx B in craniofacial hyperhidrosis.

METHODS:

The dermatology life quality index (DLQI) was monitored before and after treatment in 38 patients with craniofacial hyperhidrosis. Sweating before and after treatment was monitored by measuring trans epidermal water loss and by collecting gravimetric data. Global Assessment of Therapy in a 5-grade scale was captured.

RESULTS:

DLQI scores were significantly improved at follow-up 2-4 weeks posttreatment and sweating was significantly reduced. DLQI scores before treatment were 13 ± 1 (mean ± SD) and posttreatment 5 ± 1 which was highly statistically significant (P < 0.001). Sweating before treatment monitored with trans epidermal water loss was 52 ± 31 g/m(2) /h which decreased to 18 ± 7 g/m(2) /h (P < 0.001) posttreatment. Gravimetric data yielded a sweat rate of 0.07 ± 0.08 mg/min at baseline, which consequently dropped to 0.02 ± 0.05 mg/min (P < 0.05) posttreatment. Regarding the Global Assessment of Therapy 87% of the patients were satisfied (score 4-5) with the treatment result. In a 2-year follow-up, 74% returned for further treatments after a median time of 5 months. Side-effects were mild and most commonly reported was stiffness of the forehead and the eyebrows.

CONCLUSIONS:

In this prospective, uncontrolled study Btx B seems to be both a safe and effective treatment in craniofacial hyperhidrosis improving quality of life and reducing extreme sweating.

• Authors: M Karlqvist, K Rosell, A Rystedt, K Hymnelius, C Swartling
• Journal: Journal of the European Academy of Dermatology and Venereology : JEADV (J Eur Acad Dermatol Venereol) Vol. 28 Issue 10 Pg. 1313-7 (Oct 2014) ISSN: 1468-3083 [Electronic] England
• PMID: 24118460 (Publication Type: Journal Article)
• Copyright: © 2013 European Academy of Dermatology and Venereology.

Chemical References

• Acetylcholine Release Inhibitors
• rimabotulinumtoxinB
• Botulinum Toxins, Type A

Topics

• Acetylcholine Release Inhibitors (therapeutic use)
• Adult
• Botulinum Toxins, Type A (therapeutic use)
• Dose-Response Relationship, Drug
• Face
• Female
• Follow-Up Studies
• Humans
• Hyperhidrosis (drug therapy, physiopathology)
• Injections, Intradermal
• Male
• Prospective Studies
• Scalp
• Sweating (drug effects)
• Treatment Outcome